title: Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study.
abstract: The aim of this study was to assess the therapeutic efficacy of the serotonin norepinephrine reuptake inhibitor (SNRI), milnacipran, on both cognitive impairment and depression in post-stroke depression (PSD) patients. A total of 18 PSD patients, approximately 3 months after stroke, were divided into two groups, milnacipran and control. A total of 10 patients were assigned to the milnaciprane group and eight were assigned to control group. Their cognitive impairment and mood symptoms were measured using the Mini-Mental State Examination (MMSE) and Hamilton Depression Rating Scale (HAM-D) both at the time of admission and at discharge, an interval of approximately 3 months. This study examined the changes in both MMSE and HAM-D scores during the study period. A significant time-by-group interaction for results of the MMSE was observed, although there was no significant difference between the two groups on the HAM-D. Amelioration of cognitive impairment was greater in the milnacipran group than the control group. For PSD patients, milnacipran is effective in improving cognitive dysfunction.
authors.affiliation: Department of Psychiatry, Tsukuba Memorial Hospital, Tsukuba, Japan. ssato@bg8.so-net.ne.jp
authors.forename: Shinji
authors.initials: S
authors.lastname: Sato
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Yamakawa
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Terashima
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ohta
authors.forename: Takashi
authors.initials: T
authors.lastname: Asada
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D003521:Cyclopropanes / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D003865:Major Depressive Disorder / Q000209:etiology / Q000523:psychology; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D019964:Mood Disorders / Q000188:drug therapy / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D020521:Stroke / Q000145:classification / Q000150:complications* / Q000523:psychology; D014057:Tomography, X-Ray Computed
chemical_list: D000928:Antidepressive Agents; D003521:Cyclopropanes; D000078764:Milnacipran